Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients
Professor of Experimental Medicine
Profess Liz Ward Centre for Functioning and Health Research, Metro South Hospital and Health Service, and The Univers
Laryngectomy rehabilitation: Opportunities for improving speech pathology supports via telehealth
Prof Samuel Janes University College London Hospitals
Professor Patricia Price Action Radiotherapy
Action Radiotherapy -a charity for radiotherapy patients and professionals.